Three African countries chosen to test world's first malaria vaccine

Ghana, Kenya and Malawi to begin pilot scheme trialling experimental treatment next year

Monday 24 April 2017 13:02
Comments
A mother holds her baby receiving a new malaria vaccine as part of a trial at the Walter Reed Project Research Center in Kombewa in western Kenya
A mother holds her baby receiving a new malaria vaccine as part of a trial at the Walter Reed Project Research Center in Kombewa in western Kenya

Three African countries have been chosen to test the world's first malaria vaccine, the World Health Organisation (WHO) has announced. Ghana, Kenya and Malawi will begin piloting the injectable vaccine next year with young children, who have been at highest risk of death.

The vaccine, which has partial effectiveness, has the potential to save tens of thousands of lives if used with existing measures, the WHO regional director for Africa, Dr Matshidiso Moeti, said in a statement. The challenge is whether impoverished countries can deliver the required four doses of the vaccine for each child.

Malaria remains one of the world's most stubborn health challenges, infecting more than 200 million people every year and killing about half a million, most of them children in Africa. Bed netting and insecticides are the chief protection.

Sub-Saharan Africa is hardest hit by the disease, with about 90 percent of the world's cases in 2015. Malaria spreads when a mosquito bites someone already infected, sucks up blood and parasites, and then bites another person.

A global effort to counter malaria has led to a 62 percent cut in deaths between 2000 and 2015, WHO said. But the UN agency has said in the past that such estimates are based mostly on modelling and that data is so bad for 31 countries in Africa — including those believed to have the worst outbreaks — that it couldn't tell if cases have been rising or falling in the last 15 years.

The vaccine will be tested on children five to 17 months old to see whether its protective effects shown so far in clinical trials can hold up under real-life conditions. The vaccine has taken decades of work and hundreds of millions of dollars to develop.

Kenya, Ghana and Malawi were chosen for the vaccine pilot because all have strong prevention and vaccination programmes but continue to have high numbers of malaria cases, WHO said. The countries will deliver the vaccine through their existing vaccination programmes.

WHO is hoping to wipe out malaria by 2040 despite increasing resistance problems to both drugs and insecticides used to kill mosquitoes.

“The slow progress in this field is astonishing, given that malaria has been around for millennia and has been a major force for human evolutionary selection, shaping the genetic profiles of African populations,” Kathryn Maitland, professor of tropical paediatric infectious diseases at Imperial College London, wrote in The New England Journal of Medicine in December. “Contrast this pace of change with our progress in the treatment of HIV, a disease a little more than three decades old.”

The malaria vaccine has been developed by pharmaceutical company GlaxoSmithKline, and the $49 million for the first phase of the pilot is being funded by the global vaccine alliance GAVI, UNITAID and Global Fund to Fight AIDS, Tuberculosis and Malaria.

Southeast Asia, Latin America and the Middle East also have malaria cases.

Associated Press

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in